ATI RN
ATI Pharmacology Test Bank Questions
Question 1 of 5
A client with Hodgkin's disease is receiving Cyclophosphamide IV. Which medication should be administered concurrently to prevent an adverse effect of Cyclophosphamide?
Correct Answer: A
Rationale: Mesna, an uroprotectant agent, is administered with nitrogen mustard chemotherapy drugs like Cyclophosphamide to prevent hemorrhagic cystitis, a common adverse effect. Mesna works by binding to and inactivating the toxic metabolites of Cyclophosphamide in the bladder, thereby reducing the risk of bladder toxicity.
Question 2 of 5
When should a blood sample be obtained for a peak serum level of gentamicin when administered by IV infusion for 1 hour at 0900?
Correct Answer: B
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 3 of 5
When administering IV Amphotericin B to a client with a systemic fungal infection, the nurse should monitor the client for which of the following adverse effects of this medication?
Correct Answer: C
Rationale: The correct answer is fever. Amphotericin B is known to cause adverse effects such as fever, chills, and nausea during infusion. Monitoring for fever is essential as it can indicate an adverse reaction. To manage these effects, pretreatment with diphenhydramine and acetaminophen can be administered.
Question 4 of 5
A client starting highly active antiretroviral therapy (HAART) for HIV infection is being educated by a nurse on preventing medication resistance. What information should the nurse provide the client about resistance?
Correct Answer: C
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 5 of 5
A client has a new prescription for Enfuvirtide to treat HIV infection. The nurse should monitor the client for which of the following adverse reactions?
Correct Answer: D
Rationale: While bone marrow suppression is not typically associated with Enfuvirtide, a more relevant concern is the risk of severe allergic reactions such as anaphylaxis. Enfuvirtide, an HIV fusion inhibitor, can cause local injection site reactions and systemic allergic responses. Monitoring for signs of allergic reactions, such as rash, fever, and difficulty breathing, is crucial to ensure the client's safety.